Information for Authors

Note: These instructions comply with those formulated by the International Committee of Medical Journal Editors (ICMJE). For further details, authors should consult the following article: International Committee of Medical Journal Editors. "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" New Engl J Med 1997, 336:309–315. The complete document appears at

The Egyptian Liver Journal (EGLJ) is a peer-reviewed clinical journal published by the National Liver Institute, Menoufiya University (NLI) and the Society of Friends of Liver Patients in the Arab World (SLPAW). The Journal publishes articles describing clinical and basic research in both humans and experimental models in the fields of hepatology, hepatobiliary surgery, pediatric hepatology, clinical pathology, virology, microbiology, epidemiology and histopathology.

We ask you to confirm that your paper has not been published in its current form or a substantially similar form (in print or electronically, including on a web site), that it has not been accepted for publication elsewhere, and that it is not under consideration by another publication. The ICMJE has provided details of what is and what is not duplicate or redundant publication. If you are in doubt (particularly in the case of material that you have posted on a web site), we ask you to proceed with your submission but to include a copy of the relevant previously published work or work under consideration by other journals. In your covering letter to the editors, draw attention to any published work that concerns the same patients or subjects as the present paper.

All articles published in the journal are reviewed by at least one of the editors. Contributions will be sent for external peer review by at least two independent reviewers. Authors submitting manuscripts to the journal are invited to suggest up to 5 potential reviewers, of which at least 3 should be chosen from among the members of the Editorial Board. Manuscripts are accepted on the basis of quality, originality and interest to the readers. A paper that has been rejected cannot be re-submitted for publication without written permission from the Editorial Office that handled the original review.

The EGLJ requires authors to state all possible conflicts of interest, including financial and other relationships on a separate line in the Acknowledgements section of the paper. If you are sure that there is no conflict of interest, please state so. The ICMJE provides further information on conflicts of interest. Remember that sources of funding should also be acknowledged in your paper on a separate line in the Acknowledgements section.

The EGLJ requires you to send us copies of permission to reproduce material (such as illustrations) from the copyright holder. Articles cannot be published without these permissions.

The protection of a patient's right to privacy is essential. Please send copies of patients' consent forms on which patients or other subjects of your experiments clearly grant permission for the publication of photographs or other material that might identify them. If the consent form for your research did not specifically include this, please obtain it or remove the identifying material. 

A statement to the effect that such consent had been obtained must be included in the 'Methods' section of your paper.

All articles dealing with original human or animal data must include a statement on ethics approval at the beginning of the Methods section. In addition, for studies conducted on human participants you must state clearly that you obtained written informed consent from the study participants; please also look at the latest version of the Declaration of Helsinki. Similarly, for experiments involving animals you must state the care of animal and licensing guidelines under which the study was performed. If ethics clearance was not necessary, or if there was any deviation from these standard ethical requests, please state why it was not required. Please note that the editors may ask you to provide evidence of ethical approval. If you have approval from a National Drug Agency (or similar) please state this and provide details, this can be particularly useful when discussing the use of unlicensed drugs.

We ask all authors to confirm that they have read and approved the paper. Second, we ask all authors to confirm that they have met the criteria for authorship as established by the ICMJE, believe that the paper represents honest work, and are able to verify the validity of the results reported. 

All persons designated as authors should qualify for authorship and all those who qualify should be listed. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. One or more authors should take responsibility for the integrity of the work as a whole, from inception to published article. Authorship credit should be based only on 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published. Conditions 1, 2 and 3 must all be met. Acquisition of funding, the collection of data or general supervision of the research group, by themselves, do not justify authorship. All others who contributed to the work who are not authors should be named in the Acknowledgements section.

Papers are accepted for publication on the understanding that exclusive copyright in the paper is assigned to the Publisher. Authors are asked to sign a copyright assignment form at the revision stage and to submit it with their revised manuscript. Without the signed copyright form, the manuscript cannot be published. Authors may use material from their paper in other works published by them.


Egyptian Liver Journal accepts manuscript submissions through Editorial Manager online submission service:


The Editors will consider and publish the following:

Manuscripts describing original research must be no longer than 5,000 words, abstract of 275 words, and a title with no more than 15 words.

Rapid Communications are brief, definitive reports of unusual interest, justifying expedited review, and should be no longer than 3,000 words. A paper submitted as a rapid communication should be identified as such in the cover letter. It will undergo expedited peer review and will be published within 2 months of acceptance. Manuscripts submitted for rapid communication will be accepted or rejected at the initial disposition stage. Any revision to an accepted rapid communication must be stylistic and very minor. A rapid communication rejected at the initial disposition stage may be resubmitted for a full review.

Concise Reviews of both basic and clinical topics should be no longer than 5,000 words. The reference list need not be exhaustive.

Letters to the Editor may be subjected to peer review and undergo editing for clarity and brevity, and should be no longer than 500 words and include no more than 10 references and one figure.

Editorials are invited by the Editor or Associate Editors and should be no longer than 1,500 words.

Hepatology Elsewhere should be no longer than 1,500 words and are invited by the Editor or an Associate Editor. Suggestions for this type of manuscript should be made to the Editor or an Associate Editor. Permission from the publisher and author for the abstract to be reprinted should be included.

Image of the Issue section is designed to highlight interesting liver pathological and radiographic findings along with their clinical correlation and relevance. Submissions should be limited to no more than 500 words and include high-quality gross photos and/or histomicrograph(s) or imaging studies. These should include a brief clinical history, detailed description of the image(s), the differential diagnosis, and three to five pertinent references. The number of authors should be limited to two, with ideally one author being a pathologist or radiologist.

Case reports are clinical cases illustrating interesting clinical information and a significant advance in our understanding of disease etiology, pathogenetic mechanisms or treatment. Manuscripts should be limited to 3,000 words, two tables and/or figures, and fifteen references.

Special Articles are on a variety of topics and may include practice guidelines, in-depth scientific reviews, meeting reports, and comments on social policy. The length of each article is decided by the Editor on a case-by-case basis.

Manuscripts that exceed the word limits listed above will be returned to the authors for shortening without a full review. Manuscripts that are redundant or contain extraneous material will be returned after a full review for shortening even if otherwise acceptable.

All elements of a manuscript should be double-spaced, and all pages must be numbered in the upper right corner, starting with the title page. The acceptable font is "sans serif" Arial, font size 12. Submissions must include the following:

  1. Complete manuscript without the tables or figures as one Microsoft Word (.doc) document.
  2. Tables and Figure legends submitted separately in one Microsoft Word document.
  3. Figures submitted separately in TIFF format with a resolution of 300 dpi (dots per inch).
  4. Financial disclosure statement signed by every contributing author.
  5. Cover letter may include names of reviewers whose expertise qualifies them to review the work, and those that authors wish to exclude with the reason for exclusion to be considered by the Editors.

Full-length reports of completed research, either experimental or clinical, should not exceed 5,000 words of text, with an abstract of no more than 275 words, and a combined total of no more than 10 tables or figures.
Editorial formatting (use of italics, superscripts, Greek letter, etc.) should be consistent. For Greek letters, "Insert Symbol" should be used. Typographical formatting (column widths, type styles, etc.) should not be used. Text should be flush left; paragraphs should not be indented and should be separated by two hard returns. Do not use hard returns within paragraphs. Do not use the program's indenting or margin-setting features; these will be added during typesetting. Manuscripts must be written in clear grammatical US English. They must conform to the following order and format:

Page 1: Title page. It should include:

  1. Title: Not more than 15 words and it should not be a sentence; no drugs brand names may be used in article titles. Acronyms and abbreviations should not be used in the title.
  2. Running title: A short title of the manuscript of less than 50 characters, including the spaces.
  3. Authors: The full first name, middle initials, and family name of each author, as well as the name(s) of the department(s) and institution(s) to which the work should be attributed. Individual affiliations, departments or institutions should be indicated by a superscript Arabic number after the names and after punctuations, and before the affiliations.
  4. Keywords: 3-5 words that are significant to your article. These are to be used for indexing purposes.
  5. Word Count: Word count of abstract and word count of text should appear on this page. Text word count does not include title page, abstract, legends, tables, notes or references.
  6. Tables and Figures: List the number of tables and figures.

Page 2: Footnote page. It should include:

  1. Address for correspondence: The mailing address, telephone and fax numbers, and e-mail address for the corresponding author.
  2. List of abbreviations: List abbreviations not likely to be familiar to the reader. Abbreviations should be listed alphabetically with their expansions. Please do not abbreviate terms unless they are used more than five times in the manuscript.
  3. Financial support: List all forms of grants or other financial support received by each author for this study; list any potential conflict of interest for each author.

Page 3: Abstract. It should be no longer than 275 words for Articles. The abstract should consist of four paragraphs, labeled Background, Methods, Results, and Conclusions. They should briefly describe, respectively, the problem being addressed in the study, how the study was performed, the salient results, and what the authors conclude from the results.

Page 4 and thereafter: Main Body.

  1. Introduction: No heading should be included. It should contain a statement of the purpose of the work, the problem that stimulated it, and a brief summary of relevant published investigations.
  2. Materials and Methods: These must be presented in sufficient detail to enable other investigators to repeat the work. Citation of methods that are used without significant modification will suffice. In manuscripts presenting research that included human subjects, assurance should be provided with regards to obtaining written informed consent from each subject and that the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the appropriate institutional review committee. Refer to individual patients by numbers, not by initials.
  3. Results: The results should be concise, avoiding redundant tables and figures illustrating the same data.
  4. Discussion: This section should interpret results.
  5. Acknowledgements: This includes contributions not related to authorship, i.e. which are not substantial to the conception and design of the study, the acquisition of data, the analysis and interpretation, critical revision of the article
  6. References: Number references in the order cited in the text as superscript Arabic numerals without parentheses and after punctuations. The References section should start on a separate page. Only published works and manuscripts that have been accepted for publication should be listed in the References. For format, see the following section.

Reference Format
No more than eight authors should be listed; if more, only include the first six followed by "et al.". Titles of journal articles must be included, and abbreviation of journal names should conform to the Index Medicus style. The following are examples of the reference style (please note sequence, punctuation, and spacing):

  1. Eight authors: Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, Erlinger S, Lebrec D. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol. 1998; 29:565–70.
  2. More than eight authors: Lin RS, Lee FY, Lee SD, Tsai YT, Lin HC, Lu RH, et al. Endotoxemia in patients with chronic liver diseases, presence of relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995; 22:165–172.
  3. Book chapter: Epstein M. Peritoneovenous shunt in the management of ascites and the hepatorenal syndrome. In: Epstein M, editor. The kidney in liver disease. Philadelphia: Hanley and Belfus; 1996:491–506.
  4. National Center statistics: National Center for Health Sciences. Acute conditions: incidence and associated disability, United States July 1968–June 1969. Rockville, MD: National Center for Health Statistics, 1972. (DHEW publication No. [HSN] 72-1036).

Type each table, double-spaced throughout (including headings, footnotes and data) on a separate page. Number the tables with Arabic numerals in the order of their appearance in the text and supply a concise, informative title for each one. Each column in the tables should carry a concise heading describing the data in the column. Use lowercase superscript letters to designate footnotes and type the footnotes below the tables. Explain all abbreviations and symbols. Tables are cited in the text in numerical order. Each table should be able to be understood without consulting the text. Express temperatures as degrees Celsius and other measurements in SI units.
NB: Photographs of tables are not accepted

Figure Legends 
Legends should be supplied starting on a separate page for all figures, providing sufficient explanation for each figure to be understood independently. Explain all abbreviations and symbols. Legends should be numbered with Arabic numerals to correspond with the order mentioned in the text. All histology figures must be published in color.​